Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05347212 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
A Phase 2 study of Renal Medullary Carcinoma and Carcinomas, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05347212 is a Phase 2 study of Renal Medullary Carcinoma and Carcinomas that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05347212, a Phase 2 study of Renal Medullary Carcinoma and Carcinomas, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if the combination of nivolumab and relatlimab can help to control renal medullary carcinoma (RMC) that is locally advanced or metastatic (has spread).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Relatlimab
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2027-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05347212
The ClinicalTrials.gov registry entry for NCT05347212 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Renal Medullary Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05347212 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05347212 about?
NCT05347212 is a clinical study titled "Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla". To learn if the combination of nivolumab and relatlimab can help to control renal medullary carcinoma (RMC) that is locally advanced or metastatic (has spread).
What is the current status of trial NCT05347212?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-09-22. Estimated completion is 2027-07-16.
What conditions does trial NCT05347212 study?
This clinical trial studies the following conditions: Renal Medullary Carcinoma, Carcinomas.
What interventions are being tested in trial NCT05347212?
The interventions under investigation include: Nivolumab (DRUG), Relatlimab (DRUG).
Who is sponsoring clinical trial NCT05347212?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05347212 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Medullary Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.